Deep-brain stimulation of the human nucleus accumbens-medial septum enhances memory formation.
Journal
Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035
Informations de publication
Date de publication:
20 Nov 2023
20 Nov 2023
Historique:
pubmed:
4
12
2023
medline:
4
12
2023
entrez:
4
12
2023
Statut:
epublish
Résumé
Deep-brain stimulation (DBS) is a potential novel treatment for memory dysfunction. Current attempts to enhance memory focus on stimulating human hippocampus or entorhinal cortex. However, an alternative strategy is to stimulate brain areas providing modulatory inputs to medial temporal memory-related structures, such as the nucleus accumbens (NAc), which is implicated in enhancing episodic memory encoding. Here, we show that NAc-DBS improves episodic and spatial memory in psychiatric patients. During stimulation, NAc-DBS increased the probability that infrequent (oddball) pictures would be subsequently recollected, relative to periods off stimulation. In a second experiment, NAc-DBS improved performance in a virtual path-integration task. An optimal electrode localization analysis revealed a locus spanning postero-medio-dorsal NAc and medial septum predictive of memory improvement across both tasks. Patient structural connectivity analyses, as well as NAc-DBS-evoked hemodynamic responses in a rat model, converge on a central role for NAc in a hippocampal-mesolimbic circuit regulating encoding into long-term memory. Thus, short-lived, phasic NAc electrical stimulation dynamically improved memory, establishing a critical on-line role for human NAc in episodic memory and providing an empirical basis for considering NAc-DBS in patients with loss of memory function.
Identifiants
pubmed: 38045279
doi: 10.21203/rs.3.rs-3476665/v1
pmc: PMC10690315
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIMH NIH HHS
ID : R01 MH113929
Pays : United States
Déclaration de conflit d'intérêts
COMPETING FINANCIAL INTERESTS J.A.B. reports having received research funding from Boston Scientific and Medtronic. C.N. has received funding from Boston Scientific Ibéria. The authors declare no other competing financial interests.